How 3D Printing Could End The Deadly Shortage Of Donor Organs
Three-dimensional printing has been used to make everything from pizza to prostheses, and now researchers are working on using the emerging technology to fabricate hearts, kidneys, and other vital human organs. That would be very big news, as the number of people who desperately need an organ transplant far outstrips the number of donor organs available. On average, about 21 Americans die every day because a needed organ was unavailable. What exactly is the promise of 3D printing organs and tissues, or "bioprinting?" How does the technology work, and when might it start saving lives? For answers to these and other questions, HuffPost Science reached out to Dr. Anthony Atala (right), director of the Wake Forest Institute for Regenerative Medicine and a world-renowned expert in the field, to find out. See below for a lightly edited version of the Q &A. Can 3D printing end the shortage of organs? 3D printing is not magic. It is simply a way to scale up the current processes we use to engineer organs in the laboratory. Our team has successfully engineered bladders, cartilage, skin, urine tubes and vaginas that have been implanted in patients. Our goal is produce organ structures such as these with 3D printing to make the engineering process more precise and reproducible. The ultimate goal of regenerative medicine -– regardless of the way the organs are engineered -- is to help solve the shortage of donor organs. How might 3D-printed organs compare ...
Conditions: Kidney Failure; Liver Failure, Chronic; Kidney-Pancreas Failure Interventions: Drug: Custodiol-N Solution; Drug: Custodiol HTK Solution Sponsor: Dr. F. Köhler Chemie GmbH Not yet recruiting
Jun Zhang, Zhi Sun, Zhenfeng Zhu, Jing Yang, Jian Kang, Guiwen Feng, Lin Zhou, Lihua Zuo, Yonggang Luo, Xiaojian Zhang
Authors: Schlabe S, van Bremen K, Aldabbagh S, Glebe D, Bremer CM, Marsen T, Mellin W, Cristanziano VD, Eis-Hübinger AM, Spengler U Abstract Hepatitis B represents a global health threat because its chronic course and sequelae contribute to a high morbidity and mortality. Hepatitis B virus (HBV) infection can be controlled by vaccines, antiviral treatment, and by interrupting transmission. Rare vaccine escape mutants are serious because they eliminate vaccine protection. Here, we present a 74-year-old vaccinated patient with HBV reactivation 11 years after kidney transplantation. The patient was HBV-positive b...
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response. In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac...
Authors: Bodro M, Linares L, Chiang D, Moreno A, Cervera C Abstract INTRODUCTION: Recurrent urinary tract infections are a common clinical problem in kidney transplant recipients. Due to the complex urological anatomy derived from the implantation of the kidney graft, the spectrum of the disease and the broad underlying pathophysiological mechanisms. Recurrent urinary infections worsen the quality of life, decrease the graft survival and increase the costs of kidney transplantation. Areas covered. In this review we describe the definitions, clinical characteristics, pathophysiological mechanisms and microbiology of...
CONCLUSION: Our results indicated that late conversion to everolimus with CNI minimization in elderly recipients older than 55 years of age may be associated with more frequent adverse events and discontinuations. PMID: 30097996 [PubMed - as supplied by publisher]
CONCLUSIONS Results suggest that tacrolimus granules are well tolerated and effective in preventing transplant rejection when administered in routine practice in France. PMID: 30093607 [PubMed - in process]
Reuters Health Information
Conditions: Kidney Failure; Kidney Diseases; Hepatitis C Intervention: Drug: glecaprevir/pibrentasvir tablets Sponsor: Raymond T. Chung, MD Not yet recruiting
Condition: Kidney Transplantation Intervention: Behavioral: Qualitative interviews with participants Sponsor: Astellas Pharma Korea, Inc. Completed
More News: Cardiology | Computers | Environmental Health | Heart | Heart Transplant | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Learning | Liver | Liver Transplant | Lung Transplant | Nutrition | Pancreas | PET Scan | Science | Skin | Skin Biopsy | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology